Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuting Yan

Showing results (141-150 of 185) with videos related to

Pageof 19
Sort By:
Blood Science (Baltimore, Md.)|January 19, 2024
Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemiaYing Yu, Wenjie Xiong, Tingyu Wang, et al.
Journal of Translational Medicine|December 9, 2022
Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemiaHao Sun, Teng Fang, Tingyu Wang, et al.
Frontiers in Immunology|July 24, 2023
Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in ChinaYuting Yan, Rui Lv, Tingyu Wang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 11, 2022
Efficient delivery of Echinococcus multilocularis miRNAs using chitosan nanoparticlesYue Sun, Yongjie Kou, Xuedong He, et al.
Haematologica|January 11, 2024
Rituximab plus cyclophosphamide and dexamethasone <i>versus</i> bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trialWenjie Xiong, Rui Lyu, Ying Yu, et al.
Cancer Letters|August 22, 2013
Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancerTeng Ji, Danni Gong, Zhiqiang Han, et al.
British Journal of Haematology|July 30, 2021
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphomaRui Lyu, Tingyu Wang, Yi Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II StudyWenjie Xiong, Yuting Yan, Tingyu Wang, et al.
Cancer Research Communications|September 8, 2023
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction TreatmentJiahui Liu, Wenqiang Yan, Huishou Fan, et al.
The Oncologist|June 28, 2025
Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United StatesYuting Yan, Yin Liu, Tonglu Qiu, et al.
Pageof 19

Showing results (141-150 of 185) with videos related to

Sort By:
Pageof 19
Blood Science (Baltimore, Md.)|January 19, 2024
Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemiaYing Yu, Wenjie Xiong, Tingyu Wang, et al.
Journal of Translational Medicine|December 9, 2022
Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemiaHao Sun, Teng Fang, Tingyu Wang, et al.
Frontiers in Immunology|July 24, 2023
Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in ChinaYuting Yan, Rui Lv, Tingyu Wang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 11, 2022
Efficient delivery of Echinococcus multilocularis miRNAs using chitosan nanoparticlesYue Sun, Yongjie Kou, Xuedong He, et al.
Haematologica|January 11, 2024
Rituximab plus cyclophosphamide and dexamethasone <i>versus</i> bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trialWenjie Xiong, Rui Lyu, Ying Yu, et al.
Cancer Letters|August 22, 2013
Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancerTeng Ji, Danni Gong, Zhiqiang Han, et al.
British Journal of Haematology|July 30, 2021
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphomaRui Lyu, Tingyu Wang, Yi Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II StudyWenjie Xiong, Yuting Yan, Tingyu Wang, et al.
Cancer Research Communications|September 8, 2023
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction TreatmentJiahui Liu, Wenqiang Yan, Huishou Fan, et al.
The Oncologist|June 28, 2025
Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United StatesYuting Yan, Yin Liu, Tonglu Qiu, et al.
Pageof 19